Translational medicine is at the heart of Amsterdam Neuroscience: we aim at making seminal contributions in understanding the functioning of the human brain and the peripheral nervous system, and their disorders. This is timely since the societal burden of brain disorders is immense, and should be considered as one of the 21st century top global health challenges. Amsterdam Neuroscience will meet this challenge by seeking endurable partnerships with industry, to speed up the development of new therapies and diagnostics for patients suffering from a neurological disorder or mental illness.
We do this in particularly by building links between university labs and clinical practice, an objective supported by our so-called Industry Alliance Office (IAO) that helps our (teams of) principal investigators and clinicians to bridge the gap between academia and clinics on the one hand and biotech and pharma on the other hand.
The aim of such collaborations in our view is to transform the fundamental understanding of human biology and brain diseases into effective health measures. It is a highly interdisciplinary field that aims to combine research of universities, academic hospitals and biotech- and pharma-industry. Its goal is to accelerate discovery of disease mechanisms, identification of novel (drug) targets for intervention, and to pave the way towards drugs discovery and validation in clinical trials.